AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26612341 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 15
Study 25149412 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal single dose)
Number of subjects: 20
Study 25149412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22234020 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 mcg/kg)
Number of subjects: 60
Study 22234020 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 20107454 — intervention group
Group type: EXPERIMENTAL
Intervention: BOUNCE intervention (12-week exercise, nutrition education, and counseling)
Number of subjects: 46
Study 20107454 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 46
Study 17585031 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut-enriched meat (WM)
Number of subjects: 23
Study 17585031 — intervention group
Group type: COMPARATOR
Intervention: Control meat (CM)
Number of subjects: 23
Study 17585031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 23
Study 15324450 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct booking system for colposcopy clinic
Number of subjects: 0
Study 10936912 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory localization ability in RM
Number of subjects: 1
Study 10936912 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual localization ability in RM
Number of subjects: 1
Study 10936912 — intervention group
Group type: COMPARATOR
Intervention: Auditory localization ability in controls
Number of subjects: 1
Study 10936912 — intervention group
Group type: COMPARATOR
Intervention: Visual localization ability in controls
Number of subjects: 1
Study 9024174 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 532 (200 mg)
Number of subjects: 0
Study 9024174 — intervention group
Group type: COMPARATOR
Intervention: Losartan (100 mg)
Number of subjects: 0
Study 9024174 — intervention group
Group type: EXPERIMENTAL
Intervention: DuP 532 and Losartan (24 hours after dosing)
Number of subjects: 0
Study 8298200 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6457
Study 3477986 — intervention group
Group type: EXPERIMENTAL
Intervention: Local oestriol treatment for 3 weeks
Number of subjects: 14
Study 3477986 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar ointment without oestriol) for 3 weeks
Number of subjects: 14
Study 30631386 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of MgS 15% (450 mg)
Number of subjects: 48
Study 30631386 — intervention group
Group type: COMPARATOR
Intervention: FNB with 15 ml of lidocaine with epinephrine (300 mg) and 3 ml of normal saline solution
Number of subjects: 48
Study 27124458 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door canvassing intervention encouraging active perspective-taking
Number of subjects: 501
Study 27124458 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-door canvassing intervention
Number of subjects: 501
Study 25081522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial PRK (t-PRK)
Number of subjects: 42
Study 25081522 — intervention group
Group type: COMPARATOR
Intervention: Mechanical PRK (m-PRK)
Number of subjects: 42
Study 22882566 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 3758
Study 22882566 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 3758
Study 21095287 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy followed by direct stenting (TS)
Number of subjects: 196
Study 21095287 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon predilatation followed by stent implantation (Control)
Number of subjects: 196
Study 17917738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 ml, three injections at 6-week intervals
Number of subjects: 101
Study 17917738 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) 1.25 mg/0.05 ml and 2 mg/0.05 ml respectively, followed by two injections of IVB at 6-week intervals
Number of subjects: 101
Study 17917738 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (control group)
Number of subjects: 101
Study 15910477 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide lining
Number of subjects: 602
Study 15910477 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning-and-sealing with a smear-removing bonding system
Number of subjects: 602
Study 15910477 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin restorations
Number of subjects: 602
Study 15910477 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 602
Study 12930925 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 1572
Study 12930925 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 10904662 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 0
Study 10904662 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 0
Study 10904662 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 8843231 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with p24-VLP
Number of subjects: 74
Study 8843231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 1633902 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration only
Number of subjects: 100
Study 1633902 — intervention group
Group type: COMPARATOR
Intervention: Aspiration and flushing
Number of subjects: 100
Study 6090530 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous glucagon
Number of subjects: 18
Study 31726314 — intervention group
Group type: EXPERIMENTAL
Intervention: Claims-based follow-up
Number of subjects: 5839
Study 31726314 — intervention group
Group type: COMPARATOR
Intervention: Site-based follow-up (+CEC)
Number of subjects: 5839
Study 31726314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined claims and site-based follow-up
Number of subjects: 5839
Study 29873004 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher starting dose of basal insulin glargine (0.3 U/kg)
Number of subjects: 880
Study 29873004 — intervention group
Group type: COMPARATOR
Intervention: Standard starting dose of basal insulin glargine (0.2 U/kg)
Number of subjects: 880
Study 27346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral vitamin K (LDVK) 150 mcg daily for six months
Number of subjects: 0
Study 27346552 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 0
Study 27346552 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral vitamin K (LDVK)
Number of subjects: 0
Study 27346552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25152504 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of healthy eating and physical activity
Number of subjects: 565
Study 25152504 — intervention group
Group type: COMPARATOR
Intervention: Promotion of breast and cervical cancer screening
Number of subjects: 565
Study 22167126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight modest hyperinsulinaemia (average ≈ 286 pmol/l)
Number of subjects: 0
Study 22167126 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked hyperinsulinaemia during the clamp (average steady-state insulin ≈ 900 pmol/l)
Number of subjects: 0
Study 22167126 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in MBV during the clamp
Number of subjects: 0
Study 22167126 — intervention group
Group type: EXPERIMENTAL
Intervention: MBV after 30 min of marked hyperinsulinaemia
Number of subjects: 0
Study 19330830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 316
Study 19330830 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 316
Study 19330830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 316
Study 19330830 — intervention group
Group type: COMPARATOR
Intervention: No chemoradiation
Number of subjects: 316
Study 17484484 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 watt KTP-laser treatment for small adenomas
Number of subjects: 230
Study 17484484 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment of KTP-laser and TUR-P for great adenomas
Number of subjects: 230
Study 14666737 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum (0.0% Na Hex)
Number of subjects: 12
Study 14666737 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% sodium hexametaphosphate (Na Hex) chewing gum
Number of subjects: 12
Study 14666737 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% sodium hexametaphosphate (Na Hex) chewing gum
Number of subjects: 12
Study 14666737 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 12
Study 11053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Number of subjects: 0
Study 11053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy extract
Number of subjects: 0
Study 11053913 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid
Number of subjects: 0
Study 8855542 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 40
Study 8855542 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (UK)
Number of subjects: 40
Study 1614055 — intervention group
Group type: EXPERIMENTAL
Intervention: AluKart combined with F‐120 or FH‐160 membrane
Number of subjects: 6
Study 1614055 — intervention group
Group type: COMPARATOR
Intervention: High‐flux F‐60 polysulfone membrane
Number of subjects: 6
Study 1614055 — intervention group
Group type: EXPERIMENTAL
Intervention: AluKart combined with FH‐160
Number of subjects: 6
Study 6233917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 30
Study 6233917 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 30
Study 31111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for primary prevention of ASCVD in patients older than 75 years
Number of subjects: 0
Study 31111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment for secondary prevention of ASCVD in patients older than 75 years
Number of subjects: 0
Study 31111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment initiation before 75-80 years
Number of subjects: 0
Study 31111235 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of statin treatment when palliative treatment starts
Number of subjects: 0
Study 28095849 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced alert method (moving average weight algorithm or bio-impedance cumulative sum algorithm)
Number of subjects: 91
Study 28095849 — intervention group
Group type: COMPARATOR
Intervention: Simple alert method (increase of 2 kg in the past 3 days)
Number of subjects: 91
Study 28095849 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-impedance arm (part of advanced alert methods)
Number of subjects: 91
Study 24816164 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 13
Study 24816164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 23578453 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal-antiemetic therapy (group M) including target-controlled infusion of propofol and remifentanil, prophylactic dexamethasone 10 mg, tropisetron 4 mg, and parecoxib sodium 40 mg 30 minutes before the end of surgery
Number of subjects: 129
Study 23578453 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron control (group C) including sevoflurane and 50% nitrous oxide, prophylactic ondansetron 4 mg 30 minutes before the end of surgery
Number of subjects: 129
Study 20697267 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 0
Study 20697267 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 0
Study 19799471 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal levodopa infusion (DLI)
Number of subjects: 24
Study 19799471 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral therapy
Number of subjects: 24
Study 17101894 — intervention group
Group type: EXPERIMENTAL
Intervention: African American women
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: White women
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: African American men
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: White men
Number of subjects: 547
Study 17101894 — intervention group
Group type: EXPERIMENTAL
Intervention: African American women (younger than 65 years)
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: White women (younger than 65 years)
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: African American men (younger than 65 years)
Number of subjects: 547
Study 17101894 — intervention group
Group type: COMPARATOR
Intervention: White men (younger than 65 years)
Number of subjects: 547
Study 16945766 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant vinorelbine plus cisplatin (30 mg/m² vinorelbine plus 100 mg/m² cisplatin)
Number of subjects: 840
Study 16945766 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 840
Study 10394407 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D conformal photon radiotherapy at a dose of 66 Gy
Number of subjects: 291
Study 8871870 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 or 24 months)
Number of subjects: 26
Study 1996795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g milk chocolate‐charcoal mixture
Number of subjects: 6
Study 1996795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g SuperChar Liquid
Number of subjects: 6
Study 1996795 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g Actidose Aqua activated charcoal
Number of subjects: 6
Study 1996795 — intervention group
Group type: COMPARATOR
Intervention: SuperChar Liquid
Number of subjects: 6
Study 1996795 — intervention group
Group type: EXPERIMENTAL
Intervention: milk chocolate‐charcoal mixture
Number of subjects: 6
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpropamide
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 286
Study 6350078 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus insulin
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus chlorpropamide
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus glibenclamide
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin
Number of subjects: 286
Study 6350078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and sulphonylurea therapy
Number of subjects: 286
Study 30768656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanzania Health Information Technology (T-HIT) system used by health workers at intervention sites for 3 months.
Number of subjects: 28
Study 30768656 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no specific intervention mentioned).
Number of subjects: 28
Study 29427602 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (zip-line ride)
Number of subjects: 32
Study 29427602 — intervention group
Group type: COMPARATOR
Intervention: Control (seated-rest trial)
Number of subjects: 32
Study 27271831 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential physical rehabilitation program including individual physical therapeutic modalities, static and dynamic respiratory maneuvers, post-isometric relaxation, Vodder's manual lymphatic drainage, and autotraining
Number of subjects: 50
Study 27271831 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic physical exercises as described by T.I. Grushina
Number of subjects: 50
Study 24481686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-h small-group intervention consisting of facilitated critique of five-step framework, strategies, and pre-recorded modelled role-play.
Number of subjects: 107
Study 24481686 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 107
Study 22081522 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol 2.4 g once daily (OD)
Number of subjects: 213
Study 22081522 — intervention group
Group type: COMPARATOR
Intervention: Asacol 800 mg three times daily (TDS)
Number of subjects: 213
Study 20206793 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of oral piroxicam 20 mg
Number of subjects: 28
Study 18360335 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl
Number of subjects: 0
Study 18360335 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 0
Study 15924753 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) 200 mg/kg initial dose, repeated doses of 200, 100, and 100 mg/kg at 6-12 hour intervals, maximum of four doses if OI deteriorated by > 2 from baseline
Number of subjects: 61
Study 15924753 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf)
Number of subjects: 61
Study 15924753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 12813474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone 50 mg
Number of subjects: 8
Study 12813474 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid synthesis inhibitor metyrapone 1500 mg orally
Number of subjects: 8
Study 12813474 — intervention group
Group type: EXPERIMENTAL
Intervention: No premedication
Number of subjects: 8
Study 12813474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 12813474 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine 0.5 mg/kg
Number of subjects: 8
Study 10585796 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of co-trimoxazole
Number of subjects: 521
Study 10585796 — intervention group
Group type: COMPARATOR
Intervention: High doses of co-trimoxazole
Number of subjects: 521
Study 10585796 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 521
Study 8838489 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniject
Number of subjects: 480
Study 8838489 — intervention group
Group type: COMPARATOR
Intervention: Standard Syringe
Number of subjects: 480
Study 1654967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium 0.1 mg kg‐1
Number of subjects: 20
Study 1654967 — intervention group
Group type: COMPARATOR
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 20
Study 31037449 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dose rabeprazole (10 mg/day) + HST (7.5 g/day)
Number of subjects: 78
Study 31037449 — intervention group
Group type: COMPARATOR
Intervention: Double dose rabeprazole (20 mg/day)
Number of subjects: 78
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof) with Clearfil SE bond (CS)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof) with Xeno V (XE)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance/Pogo (EP) with Clearfil SE bond (CS)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhance/Pogo (EP) with Xeno V (XE)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex XT (Sof)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE bond (CS)
Number of subjects: 35
Study 28002695 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno V (XE)
Number of subjects: 35
Study 26431793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 764
Study 26431793 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics
Number of subjects: 764
Study 23628107 — intervention group
Group type: EXPERIMENTAL
Intervention: Online information brochure on fertility
Number of subjects: 137
Study 23628107 — intervention group
Group type: COMPARATOR
Intervention: Online information brochure on home ownership
Number of subjects: 137
Study 21993580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (estradiol associated with trimegestone)
Number of subjects: 12
Study 21993580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19447518 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon 900 or 1200 microg q2wk, or 1200 microg q4wk
Number of subjects: 458
Study 19447518 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon 180 microg qwk
Number of subjects: 458
Study 19447518 — intervention group
Group type: EXPERIMENTAL
Intervention: Albinterferon
Number of subjects: 458
Study 19447518 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential prediction algorithm based on viral kinetics at weeks 2 and 4
Number of subjects: 458
Study 17901791 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 738
Study 17901791 — intervention group
Group type: COMPARATOR
Intervention: Comparator (amoxicillin/clavulanate, ceftriaxone, clarithromycin, or erythromycin lactobinate)
Number of subjects: 738
Study 17901791 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 738
Study 15007122 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa
Number of subjects: 13
Study 15007122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11587175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hang-back recession (n=15)
Number of subjects: 54
Study 11587175 — intervention group
Group type: COMPARATOR
Intervention: Conventional recession (n=15)
Number of subjects: 54
Study 11587175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hang-back recession (n=12)
Number of subjects: 54
Study 11587175 — intervention group
Group type: COMPARATOR
Intervention: Conventional recession (n=12)
Number of subjects: 54